芪参益气滴丸联合苯磺酸左旋氨氯地平治疗冠心病心绞痛的临床研究

目的 探讨芪参益气滴丸联合苯磺酸左旋氨氯地平片治疗冠心病心绞痛的临床疗效。方法 选择2016年8月—2018年2月安康市中心医院收治的冠心病心绞痛患者120例为研究对象，将所有患者随机分为对照组和治疗组，每组各60例。对照组口服苯磺酸左旋氨氯地平片，初始剂量2.5 mg/次，1 d/次，依据患者临床反应可增大剂量至5 mg/次，1 d/次。治疗组在对照组治疗的基础饭后0.5 h口服芪参益气滴丸，0.5 g/次，3次/d。两组患者均连续治疗1个月。观察两组的临床疗效和心电图疗效，比较两组的临床症状、血清指标。结果 治疗后，对照组和治疗组的临床疗效总有效率分别为73.33%、90.00%，两组比较差异有统计学意义（P<0.05）。治疗后，对照组和治疗组的心电图疗效总有效率分别为68.33%、86.67%，两组比较差异有统计学意义（P<0.05）。治疗后，两组心绞痛发作频率、持续时间均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组明显低于对照组，同组治疗前后比较差异有统计学意义（P<0.05）。治疗后，两组超敏C反应蛋白（hs-CRP）、妊娠相关血浆蛋白A（PAPP-A）、内皮素（ET）水平均明显低于治疗前，一氧化氮（NO）水平明显高于治疗前，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组hs-CRP、PAPP-A、ET均明显低于对照组，NO明显高于对照组，同组治疗前后比较差异有统计学意义（P<0.05）。结论 芪参益气滴丸联合苯磺酸左旋氨氯地平治疗冠心病心绞痛具有较好的临床疗效，能改善临床症状，减轻炎症反应，增强血管内皮功能，且安全性较高，具有一定的临床推广应用价值。

Clinical study on Qishen Yiqi Dripping Pills combined with levamlodipine besylate in treatment of coronary heart disease with angina pectoris

Objective To investigate the clinical effect of Qishen Yiqi Dripping Pills combined with Levamlodipine Besylate Tablets in treatment of coronary heart disease with angina pectoris. Methods Patients (120 cases) with coronary heart disease with angina pectoris in Ankang Central Hospital from August 2016 to February 2018 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Levamlodipine Besylate Tablets, starting dosage 2.5 mg/time, once daily. According to the patient''s clinical response, the dosage could be increased to 5 mg/time, once daily. Patients in the treatment group were po administered with Qishen Yiqi Dripping Pills on the basis of the control group after meals 0.5 h, 0.5 g/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies and electrocardiogram efficacies were evaluated, and clinical symptoms and serum indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.33% and 90.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the electrocardiogram efficacies in the control and treatment groups were 68.33% and 86.67%, respectively, and there was difference between two groups (P<0.05). After treatment, the frequency and duration of angina attack in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the frequency and duration of angina attack in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of hs-CRP, PAPP-A, and ET in two groups were significantly decreased, but the levels of NO in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the serum indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Qishen Yiqi Dripping Pills combined with levamlodipine besylate has clinical curative effect in treatment of coronary heart disease with angina pectoris, can improve the clinical symptoms, reduce the inflammatory response, enhance the vascular endothelial function, with good safety, which has a certain clinical application value.